Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10532MR)

This product GTTS-WQ10532MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10532MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ327MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ14003MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ9483MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ8798MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ2698MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13794MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ7103MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW